<DOC>
	<DOCNO>NCT00676143</DOCNO>
	<brief_summary>This study evaluate efficacy safety multiple dos bapineuzumab patient mild moderate Alzheimer Disease . Patients receive either bapineuzumab placebo . Each patient 's participation last approximately 1.5 year .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Bapineuzumab Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD , MMSE score 1626 , brain MRI consistent diagnosis AD Concurrent use cholinesterase inhibitor memantine allow , stable . Caregiver participate able attend clinic visit patient . Significant neurological disease AD , major psychiatric disorder Contraindication undergo brain MRI ( e.g. , pacemaker , CSF shunt , foreign metal object body ) Woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>